Replies to post #163243 on Biotech Values

[jq1234]

If they hadn't hid the information the IPO wouldn't have gotten done and they may have gone out of business. They are better off defending the stock price than the alternative. The investment banks should get sued.

I don't agree here. Ataluren isn't in preclinical stage or early clinical stage currently, it has ph2b and ph3 data from two leading indications, which showed it didn't work or at least didn't work that well in the two indications IMO. So, you can't accuse anyone hiding preclinical data at this point. If investors couldn't evaluate the drug correctly based on large volume of clinical data, they couldn't evaluate it correctly based on preclinical data either.